HEPATITIS C
Rs 78,400 vs Rs 7,750 medicine: Novartis, Eli Lilly oppose bid to cut breast cancer drug prices in India
Novartis and Eli Lilly have opposed a Kerala High Court petition seeking government intervention to make two breast cancer drugs cheaper, despite their India sales accounting for less than 0.5% of global revenues. Court submissions have highlighted development, clinical-trial and manufacturing costs against the medicines’ prices in India.
Doctors once told Pamela Anderson that she would live for only some more years, with cure rate of just 10%. ‘Took everything I had…'
Pamela Anderson recently reminisced about one of the most troubling periods in her life, when she was diagnosed with hepatitis C in the late 1990s. During that era, it was considered incurable. The Baywatch star admitted that her life was turned ‘inside out’ by the diagnosis, which was a ‘death sentence’ at that time. However, by 2015, she was cured.
World Hepatitis Day: Know about causes, symptoms and risk factors
July 28 is reserved to promote awareness of this insidious and deadly virus.
Cadila seeks nod to repurpose Hepatitis C drug for COVID-19 in India
India's Cadila Healthcare Ltd has sought approval from local regulators to use a Hepatitis C drug as a treatment for COVID-19 following promising interim results from a late-stage trial, the drugmaker said on Monday.
Johnson & Johnson arm halts R&D on Hepatitis C drug
Instead, the company will focus on a cure for chronic hepatitis B, an inflammation of the liver caused by a different virus.
- Go To Page 1

95% of hepatitis patients don't notice infection
Concerns are not limited to India. The assessment shows the infection, as well as is its consequent mortality, increasing rapidly worldwide.

Cipla partners with non-profit body FIND to increase detection of Hepatitis C
The organisation works on accelerating development and delivery of affordable diagnostic tests for poverty-related diseases.

Natco Pharma signs agreement for manufacturing, sale of hepatitis C drug
Daclatasvir, discovered and developed by Bristol-Myer Squibb, is the first-in-class NS5A inhibitor used in combination with Sofosbuvir to treat patients with chronic hepatitis C virus (HCV) genotype 3 infect

Biocon introduces advanced therapy to treat Hepatitis C
Biotechnology major Biocon launches advanced novel therapy for the treatment of Hepatitis C at a fraction of the global cost.

Strides Shasun gets DCGI nod to manufacture Hepatitis C drug
Last year, Strides had entered into a licensing agreement with Gilead Sciences to bring Hepatitis C cure to 91 developing countries.

Cipla launches generic hepatitis C drug 'Hepcvir-L' in India
Cipla has launched generic tablets used for treating of hepatitis C under the brand name 'Hepcvir-L' costing Rs 25,000 for a bottle of 28 tablets in India.

New medicine for Hepatitis C treatment launched
During the conference, two new drugs were launched for treatment of Hepatitis C disease at affordable price.

Natco gets DCGI nod to launch hepatitis C drug in India
Natco Pharma has received approval from the Drugs Controller General of India (DCGI) to launch generic version of hepatitis C treatment drug in India.

Hetero receives drug controller approval for generic Daclatasvir
Daclatasvir in combination with Sofosbuvir is indicated for the treatment of Hepatitis C genotype 3 infections, which is highly prevalent in India.

Hetero gets DCGI approval to market Hepatitis C drug
Hetero is the first company in India to receive the approval for the fixed-dose combination Ledipasvir-Sofosbuvir (90mg/400mg) from DCGI.

Drug engineered from bananas could fight AIDS: Study
The new research focuses on a protein called banana lectin, or BanLec, that "reads" the sugars on the outside of both viruses and cells.

Hepatitis C infection may fuel heart disease risk
People infected with HIV are already known to have an elevated risk for heart disease but hepatitis C can spark cardiovascular damage independent of HIV.

Roche cuts Hepatitis C drug cost by 65% for government institutions
Drug major Roche has reduced the prices of its Hepatitis C treatment drug 'Exxura' by 65 per cent across all government institutions in India.

Abbott launches Hepatitis C awareness, diagnosis programme
Hepatitis C virus causes chronic infection leading to cirrhosis and may cause liver cancer.

Hepatitis C may increase cancer risk
Researchers found that cancer rates in patients with the hepatitis C virus (HCV) were significantly increased compared to the non-HCV cohort.

Mylan Pharmaceuticals launches generic hepatitis C drug MyHep in India
US-based company's Indian arm Mylan NV has launched generic Sofosbuvir tablets in strength of 400 mg under the name MyHep in the country, it said.

Cipla to launch generic Hepatitis C drug 'Hepcvir' in India
The availability of product in other markets is subject to approvals from the regulatory authorities in respective countries, Cipla said.

Dr Reddy's shares up on Hepatitis C drug launch plan
Shares of Dr Reddy's Laboratories today settled with gains of nearly 2 per cent after the firm said it is planning to launch Hepatitis C drug in the country.

Dr Reddy's to launch Hepatitis C drug in India
Sofosbuvir is a medicine used for chronic Hepatitis C infection and sold globally by Gilead Sciences Inc, under its brand Sovaldi.

Mylan expands pact with Gilead for hepatitis-C drug
Drugmaker Mylan Laboratories Ltd said it has expanded its hepatitis C licensing agreement with Gilead Sciences, a US-based biopharma company.

Gilead's hepatitis C drug licensing to benefit more patients: Sitharaman
A delegation of Gilead Sciences Inc yesterday met Commerce and Industry Minister Nirmala Sitharaman and informed about the signing of non-exclusive licensing agreements.

Cure for Hepatitis C in HIV patients on the cards
Approximately one-third of HIV patients in the US have hepatitis C, with an estimated 7 million co-infected patients worldwide.

Key part of hepatitis C virus pictured in great detail: Reports
The findings can bring an effective hepatitis C vaccine closer to reality.
Load More